Coya Therapeutics 2025 Q1 Earnings Mixed Results as Net Loss Widens 44.6%

Coya Therapeutics (COYA) reported its fiscal 2025 Q1 earnings on May 13th, 2025. The company experienced a notable increase in revenue, but its losses deepened. Analysts may find the widened net loss concerning, while the revenue growth could indicate potential for future improvement. Coya's guidance remains focused on advancing clinical trials for its innovative therapies in regulatory T cell dysfunction.

Coya Therapeutics reported a remarkable 103.3% increase in total revenue for 2025 Q1, reaching $257,884, up from $126,838 in the same quarter of the previous year. This growth was driven entirely by collaboration revenue.

Coya Therapeutics's net loss widened to $7.31 million in 2025 Q1, a 44.6% increase from the $5.05 million loss in 2024 Q1. The company's earnings per share declined, with a loss of $0.44 per share compared to a loss of $0.35 per share in the previous year's quarter. The increased net loss reflects the company's ongoing investment in research and development. EPS indicates a challenging quarter for Coya.

Price Action

The stock price of Coya Therapeutics experienced a 5.88% drop on the latest trading day and a 0.86% decline over the past week, despite a 16.84% surge month-to-date. This mixed performance follows the company's earnings release, where the financial results showed increased revenue alongside a widened net loss. The market's reaction highlights investor uncertainty regarding the company's financial trajectory. Despite the recent gains earlier in the month, the stock faced pressure, possibly due to concerns over the increased losses. However, the company continues to advance its clinical trials, which may influence future stock performance upon successful milestones and regulatory approvals. Investors remain watchful for further developments in Coya's innovative therapies pipeline and its potential impact on long-term growth and profitability.

CEO Commentary

Arun Swaminathan, Ph.D., Chief Executive Officer, highlighted that recent data from the investigator-initiated trial (IIT) in patients with Frontotemporal Dementia (FTD) and the encouraging results from COYA 303 underscore the potential of their approach to address regulatory T cell (Treg) dysfunction. He expressed confidence in the clinical outcomes for the upcoming COYA-302 studies in Amyotrophic Lateral Sclerosis (ALS) and FTD, reinforcing the company’s commitment to its innovative combination therapies.

Guidance

Coya Therapeutics anticipates submitting additional nonclinical data to support the COYA 302 Phase 2 trial in ALS by the end of Q2 2025, with plans to initiate a controlled Phase 2 clinical trial following IND acceptance. The company also expects to file an IND for FTD by year-end, aiming for a controlled Phase 2 trial initiation thereafter.

Additional News

In recent weeks, Coya Therapeutics has announced significant strategic developments. The company expanded its product pipeline by introducing COYA 303 and COYA 301 in combination with GLP-1 Receptor Agonists for treating inflammatory diseases. This expansion is complemented by the filing of a new intellectual property portfolio, underscoring Coya's commitment to innovative treatment solutions. Additionally, Coya welcomed new institutional investments, including a $5 million strategic investment by the Alzheimer’s Drug Discovery Foundation to support the development of COYA 302 for Frontotemporal Dementia. Furthermore, Coya has been actively engaging in research collaborations to advance understanding and treatment of neurodegenerative diseases, solidifying its position as a leader in regulatory T cell-focused therapies.